Chronic congestive heart failure
Conditions
Interventions
Tolvaptan
Furosemide
Sponsors
Department of Cardiology, Gifu University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients of congestive heart failure hospitalized with the chronic kidney disease that presented body fluid retention even if taken more than furosemide 20mg/day.
Exclusion criteria
Exclusion criteria: Patients who had acute myocardial infarction within 30 days . Patients of active myocarditis or the amyloid cardiomyopathy. Patients who are supported by circulation device. Patients who had decrease in circulation blood volume. Patients with hypertrophic cardiomyopathy (except the expansion aspect). Patients with severe valvular disease. Patients with hepatogenic comatose. Patients with insufficient treatment on diabetes mellitus. Patients whose blood pressure is less than 90mmHg. Patients that following electrolytes abnormality is accepted. Serum Na>147mEq/L, serum K>5.5mEq/L Patients who cannot take oral formulation. Patients with a pregnant woman, a nursing girl, pregnant possibility or the intention to become pregnant. Patients that are recognized as inappropriate for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement effect of the heart failure | — |
Secondary
| Measure | Time frame |
|---|---|
| BNP, renin activity, aldosteron, catecholamine, CRE, cystatin C, urine L-FABP | — |
Countries
Japan
Contacts
Public ContactShinya Minatoguchi
Gifu University Graduate School of Medicine Department of Cardiology
Outcome results
None listed